BridgeBio Pharma Inc (BBIO) Stock Analysis

BridgeBio Pharma Inc (BBIO) is a publicly traded company in the HEALTHCARE sector. It trades at $63.88, carries a market capitalization of $12.80B. This page summarizes the public market data, fundamentals, and frequently asked questions for BBIO, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $63.88
• Market Cap: $12.80B
• EPS: $-3.74
• 52-Week High: $84.94
• 52-Week Low: $37.57

Market Sentiment

BridgeBio Pharma Inc currently has a Bullish sentiment score of 0.39.

About BridgeBio Pharma Inc

BridgeBio Pharma, Inc. is an innovative biopharmaceutical company headquartered in Palo Alto, California, specializing in the discovery, development, and commercialization of therapies targeting genetic diseases and rare disorders. Leveraging cutting-edge scientific methodologies and a deep understanding of genetic medicine, BridgeBio is committed to addressing significant unmet medical needs, showcasing a diverse pipeline of product candidates with the potential to transform patient care. As...

GNG Research Analysis

GNG Research scores BridgeBio Pharma Inc (BBIO) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for BBIO.

Frequently Asked Questions

Does BBIO pay dividends?

BridgeBio Pharma Inc (BBIO) does not currently pay a regular dividend.

What is BBIO's market cap?

BridgeBio Pharma Inc (BBIO) has a market capitalization of $12.80B with a current stock price of $63.88.